210 - T-Cell Modifying Therapies: What the ID Provider Needs to Know

Wednesday, October 22, 2025

10:30 AM - 11:45 AM US ET

Location: B405-B407

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Murat Akova, Prof. (he/him/his)

Professor
Hacettepe University
Ankara, Ankara, Turkey
Joshua A. Hill, MD

Associate Professor
Fred Hutch Cancer Center

Faculty(s)

BT

Benjamin Teh, MD

Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Jessica Little, MD (she/her/hers)

Transplant Infectious Diseases Physician
Brigham and Women's Hospital
Boston, MA, United States
SS

Susan Seo, MD

Director, Antibiotic Management Program
Infectious Diseases Service
Memorial Sloan Kettering
New York, NY, United States

Disclosure(s):

Murat Akova, Prof.: No financial relationships to disclose.

Joshua A. Hill, MD: AlloVir: Advisor/Consultant, Grant/Research Support; Century Therapeutics: Advisor/Consultant; CSL Behring: Advisor/Consultant; ExeVir Bio: Advisor/Consultant; GeoVax: Advisor/Consultant, Grant/Research Support; Gilead Australia: Honoraria; Grifols: Advisor/Consultant; Karius: Advisor/Consultant, Travel; Medscape: Advisor/Consultant; Merck: Grant/Research Support; Moderna, Inc.: Board Member; Modulus: Advisor/Consultant; Oxford immunotec: Grant/Research Support; Sanofi Pasteur Inc.: Advisor/Consultant; Senti BioSciences, Inc: Advisor/Consultant; SymBio: Advisor/Consultant; Takeda: Grant/Research Support; Takeda Netherlands: Honoraria; UpToDate: Royalties

Benjamin Teh, MD: No financial relationships to disclose.

Jessica S. Little, MD: Merck and Company, Inc.: Grant/Research Support; Moderna, Inc.: Grant/Research Support

Susan K. Seo, MD: No financial relationships to disclose.

Learning Objectives:

At the conclusion of this session, participants will be able to:

descibe the basics of T-cell modifying therapies in hematology and oncology patients;
identify infections in patients receiving CAR-T cell therapy and bispecific T-cell engagers;
define the preventive strategies including vaccination and antimicrobial prophylaxis in patients receiving T-cell modifying therapies.

Presentations:

10:30 AM - 10:55 AM US ET

Overview of the Patient Journey and Risk For Infection: CAR T-Cell and Bispecific Antibody Therapy
Speaker: Susan K. Seo, MD – Memorial Sloan Kettering
10:55 AM - 11:20 AM US ET

Not All CARs and Abs Are Created Equal: Incidence, Type and Timing of Infections
Speaker: Jessica S. Little, MD (she/her/hers) – Brigham and Women's Hospital
11:20 AM - 11:45 AM US ET

Preventative Strategies: Vaccination and Prophylaxis
Speaker: Benjamin Teh, MD – Peter MacCallum Cancer Centre